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Background: Allergic bronchopulmonary aspergillosis (ABPA) is a complicating factor in cystic ﬁbrosis (CF), affecting 2–15% of patients. We
hypothesized that sensitization/challenge of CFTR−/− mice with an Aspergillus fumigatus (Af) extract will affect eicosanoid pathway gene
expression, impacting ABPA and CF.
Methods: FABP-hCFTR+/−-CFTR−/− mice were sensitized/challenged with an Af extract and gene expression of lung mRNA was evaluated for
N40 genes, with correlative data in human CF (IB3.1) and CFTR-corrected (S9) bronchoepithelial cell lines.
Results: Pla2g4c, Pla2g2c, Pla2g2d and Pla2g5 were induced in response to Af in CFTR−/− mice. Interestingly, PLA2G2D was induced by LPS,
IL-2, IL-6, IL-13, and Af only in CFTR-deﬁcient human IB3.1 cells. Prostanoid gene expression was relatively constant, however, several 12/15-
lipoxygenase genes were induced in response to Af. Numerous cytokines also caused differential expression of ALOX15 only in IB3.1 cells.
Conclusions: The distinct regulation of PLA2G4C, PLA2G2D and ALOX15 genes in Aspergillus sensitization and/or cystic ﬁbrosis could provide
new insights into diagnosis and treatment of ABPA and CF.
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The eicosanoid pathway plays a defining role in inflammation,
producing bioactive lipids which modulate both the onset of
inflammation and its resolution. Hydrolytic cleavage of arachidon-
ic acid (AA) from the phospholipid membrane is followed by
metabolism of AA by the cyclooxygenases and lipoxygenases
leading to the production of downstream prostaglandins (PGs) and
leukotrienes (LTs), respectively. These pro- and anti-inflammatory
lipidmediators orchestratemany aspects of inflammation including
vasodilation, vascular permeability, bronchoconstriction, chemo-
taxis, and the transcription of pro-inflammatory enzymes; thus they
are critical to several diseases such as asthma and cystic fibrosis
(CF) [1–3]. Specifically in CF, the fatty acid profile is skewedby Elsevier B.V. All rights reserved.
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increased production of this precursor or decreased metabolism
into the downstream products [2,3].
Within these pathophysiological events, the PGs and LTs
regulate many aspects of airway inflammation and reactivity.
Prostaglandins normally maintain a balance in airway responsive-
ness; both PGD2 and thromboxane A2 are bronchoconstrictors,
while PGE2 and prostacyclin serve in bronchoprotection [1]. On
the other hand, the action of LTs appears to be principally pro-
inflammatory, with LTB4 possessing potent chemoattractive
activity for neutrophils and eosinophils in the airways [4].
Furthermore, the cysteinyl leukotrienes (cysLTs), LTC4, LTD4
and LTE4, elicit bronchoconstriction and increased endothelial
membrane permeability leading to airway edema and enhanced
mucosal secretion, which are also physiological hallmarks of
asthma [5].
Due to this complex balance and the changes in eicosanoid
metabolism that occur in CF, we hypothesized that a more detailed
evaluation of eicosanoid gene expression in an animal model of
asthma superimposed on CF would be valuable in predicting other
therapeutic targets in eicosanoid metabolism. We developed a
model of allergic bronchopulmonary aspergillosis (ABPA)/allergic
asthma which employs crude Aspergillus fumigatus (Af) extract as
the sensitizing and challenging agent and evaluated this in a cystic
fibrosis transmembrane conductance regulator knockout (FABP-
hCFTR+/−-CFTR−/−) mouse [6]. A CFTR−/− mouse model was
used because asthma and Af sensitization are both potential
complications in CF patients due to the inability to effectively clear
secretions leading to infection and increased inflammation [7,8].
Af-sensitized/challenged mice develop a Th2 mediated allergic
inflammatory response, including elevated levels of the Th2
cytokines, IL-4, IL-5 and IL-13, and increased total serum IgE,
goblet cell hyperplasia and airway eosinophilia [6]. More
specifically, an increase in Af-specific IgE and IgG is found in
the serum of sensitized mice, demonstrating an Af-specific immune
response [6]. In the present study, the gene expression levels of
numerous enzymes involved in eicosanoid metabolism are
analyzed by real-time RT-PCR after Af sensitization and challenge
in CFTR−/− mice with comparisons in human CF derived and
normal bronchial epithelial cell lines. Our data demonstrate
alterations in gene expression for a unique subset of eicosanoid
pathway enzymes whichmay provide relevant alternative targets in
the development of markers and therapeutic regimens for CF.
2. Material and methods
2.1. Mouse strains
The original CFTR−/− mice were generated from the
embryonic stem cell line, E14TGa, derived from 129/Ola mice
and maintained on a C57BL/6 background [9]. Zhou et al.
corrected the intestinal CFTR deficits by generating a transgenic
mouse expressing the human CFTR gene (hCFTR) driven by the
intestinal specific fatty acid binding protein (FABP) promoter
[10]. These corrected mice, FABP-hCFTR+/−-CFTR−/− mice
have a mixed background of 129/Ola, C57BL/6 and FVB/N
[6,9,10]. In this manuscript, CFTR−/− refers to the mixedbackground intestinally corrected mice. CFTR−/−, C57BL/6,
and FVB mice were housed in the SPF facility of the University
of Florida according to NIH guidelines. All experiments were
approved by the IACUC of the University of Florida.
2.2. Sensitization and challenge
Animals were sensitized with a single lot of A. fumigatus
extract (Af) (XPM3D3A4, Greer Laboratories) by intraperitoneal
injections on days 0 and 14 and subsequently aerosol challenged
in an acrylic chamber with nebulizedAf extract on days 28, 29 and
30 as previously described [6]. A subset of mice was similarly
sensitized and challenged with ovalbumin (OVA) while non-
sensitized mice were mock-sensitized with PBS and similarly
challenged with Af.
2.3. Lung mRNA extraction and real-time RT-PCR
Whole lungs from mice were flash frozen in liquid nitrogen
and total RNA was isolated as per the Chomczynski and Sacchi
method with modifications [11,12]. cDNA was produced with
the SuperScript first-strand synthesis Kit (Invitrogen) and
subsequently utilized for real-time RT-PCR with 1× SYBR
Green (Applied Biosystems, Bio-Rad). Reactions were carried
out in an ABI Sequence Detection System 7000 and relative fold
changes were determined using theΔΔCTmethod normalized to
cyclophilin A. Briefly, the difference between crossing threshold
(CT) values of the target and control genes representsΔCT value.
The difference between theΔCT value for any given sample and
the control sample generates the ΔΔCT value. 2−ΔΔCT provides
the relative fold change for each sample compared to the control,
which is normalized to 1. Primers used are listed in Supplemental
Table 1. Human and mouse gene symbols, based on HUGO and
Mouse Genome Informatics guidelines, used throughout this
study are detailed in Supplemental Table 2.
2.4. Tissue culture
SV40 T-antigen transformed human bronchial epithelial cells
from a CF patient (IB3.1) [13] and IB3.1 cells corrected through
the expression of an AAV inserted functional CFTR gene (S9) [14]
weremaintained in Ham's F12Kmedium (Life Technologies) with
10% fetal bovine serum, 10 μg/mL penicillin G, 0.1 mg/mL
streptomycin and 0.25 μg/mL amphotericin B at 37 °C in 5%
CO2. Cells were grown to 70–75% confluency before 12 h of
treatment with pharmacologic agents and/or cytokines. Treatment
concentrations were as follows: Af, 100 μg/mL; LPS, 0.5 μg/mL;
IFNγ, 5 ng/mL; TNF-α, 10 ng/mL; IL-1β, 2 ng/mL; IL-2,
5 ng/mL; IL-3, 5 ng/mL; IL-4, 20 ng/mL; IL-6 10 ng/mL; IL-10,
20 ng/mL; and IL-13, 20 ng/mL.
2.5. Statistical analysis
The data from each group of mice were pooled and analyzed
by two-tailed unpaired Student's t-tests. Cell line studies were
performed based on animal data and were analyzed by one-tailed
Fig. 1. Secretory phospholipase A2 steady state mRNA levels in mouse lungs
and human cell lines. (A) CFTR−/− mice were sensitized/challenged with PBS
or Af. Real-time RT-PCR was performed from whole lung mRNA for groups II,
V, X and XII PLA2s: Pla2g2c, Pla2g2d, Pla2g2e, Pla2g5, Pla2g10 and
Pla2g12b. Data points are the means of 2−ΔΔCT±SEM (7≤n≤10). * indicates
p≤0.05 as compared to PBS-sensitized mice. (B) Real-time RT-PCR of
PLA2G2D following a 12 h treatment of S9 and IB3.1 cells with the indicated
inflammatory stimuli. Data points are the means of 2−ΔΔCT±SEM (n=3).
* and + indicate p≤0.05 as compared to IB3.1 control and treated S9 cells,
respectively.
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as p≤0.05.
3. Results
3.1. Allergic and inflammatory model in CF
We previously evaluated Af extract as an allergen in C57BL/6
and CFTR−/− mice as a model of allergic asthma demonstrating
that Af-sensitized mice develop a Th2-mediated response as seen in
asthma with increases in total serum IgE, goblet cell hyperplasia
and airway eosinophilia [6]. As indicated in 2.1 Material and
methods, we chose a mixed background mouse strain, FABP-
hCFTR+/−-CFTR−/− [6,9,10], which may be more analogous to a
genetically and immunologically diverse human population. We
have performed similar analyses in two normal inbred mouse
strains, C57BL/6 and FVB (summarized in Table 2), due to their
contribution to the mixed background of the FABP-hCFTR+/−
-CFTR−/− mice [6,9,10]. It should be noted that even if a gene
responds differently in the knockout mouse compared to each of
the background strains, it is impossible to conclude whether
differences are due to the CFTR gene ablation or a combination of
factors arising from the mix strain background. Therefore, any
response due to the lack of a functional CFTR was further
substantiated in human cell lines. Specifically, we have utilized
bronchoepithelial cells isolated from a cystic fibrosis patient and
immortalized with a hybrid virus, adeno-12-SV40 expressing
SV40 T-antigen, IB3.1 [13]. As a control, we provide results from
the S9 cell line, derived from the IB3.1 cell line by introduction of
a wild-type CFTR gene harbored in an adeno-associated viral
vector [15]. Differences between the CF cell line, IB3.1, and the
corrected S9 cells have been previously highlighted electrophys-
iologically [16] and in the inflammatory response [17], with the
consistent implication that S9 cells behave similarly to normal
bronchoepithelial cells. In this way, the mixed background of
the mice allows for observations that may be linked to the CFTR
gene, while subsequent studies in the human cell lines allow for a
direct comparison in which the only difference is the presence of
a functional CFTR.
Our previous study evaluated the induction of specific cytokines
and chemokines in Af sensitized/challenged C57BL/6 and
CFTR−/− mice [6] with similar results in FVB mice (data not
shown). To further demonstrate the effectiveness of Af in lung
inflammation, we studied the induction of similar inflammatory
mediators in response to Af compared to the more commonly used
sensitizing antigen, ovalbumin (OVA). These results demonstrated
a similar response with only a difference in magnitude between Af
and OVA-treated animals (Supp. Fig. 1). As a clinically relevant
antigen, this comparison with OVA further validates the use of Af
as an experimentally relevant allergen.
3.2. Gene expression of the phospholipase A2s
Given the importance of eicosanoids in lung disease [18],
including CF [3], we next studied changes in lung gene
expression for a large repertoire of enzymes involved in the
eicosanoid pathway in Af sensitization/challenge in CFTR−/−mice. This pathway (Supp. Fig. 2) was targeted due to the
compounding clinical manifestations of asthma in some CF
patients with linkage to A. fumigatus [19]. Supplemental Table 2
summarizes all the genes analyzed for lung expression providing
both the mouse and human gene names and symbols with
corresponding NCBI accession numbers. We first evaluated the
phospholipase A2 (PLA2) family, composed of several groups of
secretory PLA2s and two groups of cytosolic PLA2s, groups IV
(cPLA2s) and VI (iPLA2s), which is responsible for the initial
release of the primary metabolite, arachidonic acid (AA). Lung
gene expression was increased for three secretory phospholi-
pases, Pla2g2c, Pla2g2d and Pla2g5, in Af sensitization/challenge
CFTR−/− mice compared to PBS (Fig. 1A). We previously
studied these genes in C57BL/6 mice, where only Pla2g2e and
Pla2g5 were induced. All of these results and data from C57BL/6
[20] and FVB mice are summarized in Table 2.
Due to the significant response seen by Pla2g2d and Pla2g5
in CFTR−/− mice, we then studied the homologous genes in
human IB3.1 and S9 cells. Of these two cell lines, only IB3.1
demonstrated an induction of PLA2G2D in response to a panel
of stimuli (Fig. 1B). In the case of PLA2G5, we observed an
induction in both cell lines only in response to TNF-α (data not
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various cytokines, including IL-6, IL-10, IFNγ, and TNF-α, are
elicited from murine primary alveolar macrophages in response
to the Af extract, providing additional relevance to these stimuli
[20].
We next evaluated the expression levels of threemembers of the
group IV cytosolic phospholipases (cPLA2), Pla2g4a, Pla2g4b,
and Pla2g4c, with only Pla2g4c expression displaying a significant
increase in Af-sensitized/challenged CFTR−/− mice (Fig. 2). We
observed a similar response in C57BL/6 [20] and FVB mice
(Table 2), as well as an analogous induction of Pla2g4c mRNA
levels by OVA-sensitization/challenge, in support of the experi-
mental relevance of Af as a sensitizing agent (Supp. Fig. 3). We
similarly tested the expression of PLA2G4C in IB3.1 cells which
displayed substantial inductions by the pro-inflammatory stimuli
TNF-α and IL-1β (Table 1), with no significant differences as
compared to our results in S9 cells [20].
3.3. Gene expression analysis of enzymes involved in
prostanoid synthesis
Eicosanoid biosynthesis following the liberation of AA from
membrane phospholipids can result in the metabolism of AA
by cyclooxygenases (COXs) and specific downstream synthases
or lipoxygenases (LOXs). The relative expression levels of
cyclooxygenases (Ptgs1 and Ptgs2), microsomal prostaglandin E
synthase-1 (Ptges), thromboxane A2 synthase (Tbxas1), lipocalin-
type prostaglandin D synthase (Ptgds) and prostaglandin I2
synthase (Ptgis) were analyzed. We observed a small upward
trend in the expression of Ptgs1, Ptgs2 and Ptges in the CFTR−/−
mice (Fig. 3). This small increase in Ptges was also observed in
C57BL/6 mice (Supp. Fig. 4) and summarized in Table 2. With no
statistical significance to these trends, follow-up studies were not
performed in human cell lines.
3.4. Gene expression analysis of enzymes involved in
leukotriene (LT), HPETE and HETE synthesisFig. 2. Group IV cytosolic phospholipase A2s steady state mRNA levels in
mouse lungs. CFTR−/− mice were sensitized/challenged with PBS or Af as
described in Fig. 1. Real-time RT-PCR was then used to determine the steady
state mRNA levels from whole lungs for the group IV PLA2s, Pla2g4a, Pla2g4b
and Pla2g4c. * indicates p≤0.05 as compared to PBS-sensitized mice.The alternate fate of AA is peroxidation by the lipoxygenase
(LOX) family of enzymes leading to the production of lipoxins
and leukotrienes (LTs). The LTs have physiological roles in innate
immune responses in the lung and in the pathology of
inflammatory diseases, such as asthma, allergic rhinitis and
atherosclerosis [21]. Fig. 4A illustrates that the gene expression
levels for Aloxe3, Alox5 and Alox5ap are not elevated in the
CFTR−/− mice. We also evaluated other members of the LOX
family: Alox12 (platelet 12(S)-LOX); Alox12b (Epidermis-type,
12(R)-LOX); Alox15 (12-LOX Leukocyte-type, human ortholog
15-LOX-A); Alox8 (8-LOX, human ortholog 15-LOX-B); and
Alox12e (human ortholog pseudogene ALOX12P2) (Fig. 4A).
These results demonstrate significant increases in the expression
of most of the 12 and 15 LOXs in response to Af sensitization/
challenge. The results in the CFTR−/−mice are consistent with our
observations in C57BL/6 (Supp. Fig. 5A–B) and FVB mice as
summarized in Table 2.
Based on these findings, we next evaluated the human
orthologs, ALOX15 (Fig. 4B) and ALOX15B (Fig. 4C), in
IB3.1 and S9 cells in response to various inflammatory mediators.
We did not study Alox12e because this gene only exists in humans
as a pseudogene (ALOX12P). Of note, several stimuli caused an
upward trend in ALOX15 gene expression which occurred only
in the IB3.1 cells (Fig. 4B). Similarly, we observed upward trends
for various stimuli for ALOX15B gene expression primarily in
the IB3.1 cells (Fig. 4C). The extremely low cellular abundance of
both ALOX15 and ALOX15B mRNA in these cells leads to a
high variance between levels of induction. Thus, despite the lack
of statistical significance, we believe that these trends represent a
true induction based on our experience with low abundance genes
by using multiple PCR primer sets and corroboration by northern
analysis.
4. Discussion
Eicosanoids constitute a diverse family of physiologically
active fatty acids involved in regulating airway inflammation
and reactivity, which are linked to diseases such as asthma and
CF [1–3]. Recent studies have linked the ubiquitous fungus
A. fumigatus (Af ) with an increased prevalence in both asthmatics
[22,23] and cystic fibrosis patients [24]. Therefore, we employed a
mouse model that could mimic the pathology of allergen-induced
asthma using an Af extract for sensitization and challenge. We
hypothesized that potentially distinct enzymes in the eicosanoid
pathway may display altered levels of gene expression in response
to sensitization/challenge to this environmentally relevant allergen
and the resulting inflammatory response, thus highlighting poten-
tially novel therapeutic targets.
Our examination of the phospholipases (PLA2s) provides new
insights into the role these enzymes may play in asthma and CF.
To support our observations in the CFTR−/− mice, observed
changes were validated in a human CF cell line alongside a cell
line containing a functional CFTR as the only difference. Our
data highlight potential new roles for Pla2g2c, Pla2g2d and
Pla2g5 in allergen sensitization/challenge, based on the selective
induction of these sPLA2s in the CFTR
−/− mice (Fig. 1A). We
have also corroborated the CF specific induction of PLA2G2D by
Fig. 3. Gene expression analysis of enzymes involved in prostanoid synthesis in
mouse lungs. CFTR−/− mice were sensitized/challenged as described in Fig. 1,
and real-time RT-PCR on whole lung mRNA was performed for Ptgs1, Ptgs2,
Ptges, Tbxas1, Ptgds, and Ptgis. Data points are the means of 2−ΔΔCT±SEM
(7≤n≤10).
Table 1
Fold change of PLA2G4C in S9 and IB3.1 cells.
LPS IFNγ TNFα IL-1β IL-2 IL-3 IL-4 IL-6 IL-10 IL-13 Af
S9 a 1.2±0.1 0.9±0.1 6.4±1.0 ⁎ 3.0±0.2 ⁎ 1.3±0.1 1.4±0.3 1.1±0.1 1.4±0.1 ⁎ 1.2±0.1 ⁎ 1.0±0.1 1.0±0.1
IB3.1 1.1±0.1 0.8±0.1 5.7±1.7 ⁎ 2.9±0.1 ⁎ 1.4±0.3 1.4±0.2 1.0±0.1 1.3±0.0 ⁎ 1.1±0.1 1.2±0.1 1.4±0.1 ⁎
⁎ p≤0.05 by Student's t-test as compared to respective untreated cells.
a Originally published in Reference [20] — PLA2G4C data in S9 cells.
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preferentially induce expression in the IB3.1 cells (LPS, IL-2,
IL-6, IL-13, Af) (Fig. 1B). The unique expression in IB3.1 cells
versus the corrected S9 may provide a relevant linkage to CF
pathophysiology (Fig. 1B). Furthermore, the induction of
PLA2G2D by IL-6 and IL-13 is a new observation in any cell
type, since the only stimuli documented to induce this gene are
IFN-γ and LPS [25].
We next examined the group IV PLA2s, which have been
directly linked to the liberation of AA as a consequence of the
inflammatory response [26]. The vast majority of studies have
focused on PLA2G4A/cPLA2α, which responds to a variety of
stimuli and is regulated both at the transcriptional and post-
translational levels [27]. Most surprisingly, we observed an
induction of Pla2g4c in all mouse strains with no effect on
Pla2g4a or Pla2g4b (Fig. 2 and Table 2). Furthermore, confirming
that this allergic response is not antigen specific, Pla2g4c was also
induced by OVA (Supp Fig. 3). This gene was similarly induced in
both the IB3.1 and S9 cell lines by TNF-α and IL-1β (Table 1),
implicating its potential importance to the inflammatory response.
We believe that PLA2G4C responds to the allergic asthmatic
response, with no appreciable contributions to this induction
from the presence of the CFTR gene. We have also recently
demonstrated that the induction of PLA2G4C specifically involves
a promoter proximal element mediated by the transcription factors
ATF-2/cJun, p65, and USF1/2 [20]. To date, the precise
physiological role for PLA2G4C/cPLA2γ has not been elucidated;
it was first identified by orthology to PLA2G4A, to which it has
~30% overall sequence identity [28–32]. In addition to its PLA2
activities, Yamashita et al. [29] have also reported that this enzyme
displays coenzyme A (CoA)‐independent transacylation and
lysophospholipid (LPL) dismutase (LPLase/transacylase) activi-
ties and have suggested a possible role in fatty acid remodeling
of phospholipids and the clearance of toxic lysophospholipids.
Our new data in both allergic asthma and inflammation add
impetus to further studies of this gene.
Another interesting result is the lack of a significant response
from the enzymes on the cyclooxygenase branch of AA
metabolism (Fig. 3 and Supp. Fig. 4), which, at least at the
transcriptional level, implies that the prostanoids may have a
limited role in this allergy model. These data directed our attention
to the lipoxygenase branch where the literature [21,33] and the
significant pharmaceutical investment in anti-LT therapies would
argue that alterations in the expression of either Alox5 (5-LOX) or
Alox5ap (FLAP) in response to Af could be expected. As with the
prostanoid enzymes, we saw no changes with either of these
enzymes or in the levels of Aloxe3 (Fig. 4A).Af sensitization/challenge did, however, cause a significant
increase in Alox15, Alox8 and the mouse specific Alox12e.
Consistent with these data was the induction, only in IB3.1
cells, of the human ALOX15 (ortholog of mouse Alox15) by
TNF-α, IL-3, and Af (Fig. 4B) and ALOX15B (ortholog of
mouse Alox8) by IL-13 (Fig. 4C). The lack of response in S9
cells may be indicative of a more complex interplay between
CFTR and ALOX15. ALOX15 has been previously shown to
be regulated by IL-4 and IL-13 [34,35], however, no previous
studies have linked induction of ALOX15 to TNF-α or IL-3.
Our mouse data for Alox15 induction are also in line with
recent studies by Andersson et al. [36] which demonstrated that
Alox15−/− mice in a systemic OVA sensitization model had
impaired airway inflammation, reduced levels of eosinophils,
lymphocytes and macrophages in BAL fluid along with lower
levels of the Th2 cytokines (IL-4, IL-5 and IL-13) and tissue
eosinophils. Our data and that of Andersson et al. [36] would
imply that Alox15 inhibition may provide an alternative
therapeutic target for asthma and CF patients. This would also
be consistent with studies that have demonstrated an increased
level of 15-LOX metabolites in asthmatics, where 15(S)-HETE
levels in BALF were elevated and associated with tissue
eosinophil numbers, sub-membrane thickness and the observa-
tion that severe asthmatics presenting with persistent airway
eosinophils exhibit high levels of 15(S)-HETE in BALF
[37,38].
Fig. 4. Gene expression analysis of enzymes in the lipoxygenase pathway in
mouse lungs and human cell lines. (A) CFTR−/− mice were sensitized/
challenged with PBS or Af, and whole lung mRNA was analyzed by real-time
RT-PCR for lipoxygenase gene expression (Aloxe3, Alox5, Alox5ap, Alox12,
Alox12b, Alox15, Alox8, and Alox12e). Data points are the means of 2−ΔΔCT±
SEM (7≤n≤10). * indicates p≤0.05 as compared to PBS-sensitized mice.
(B) Steady state mRNA levels of human ALOX15 in response to the indicated
stimuli in S9 or IB3.1 cells. Data points are the means of 2−ΔΔCT SEM (n=3).
(C) Steady state mRNA levels of human ALOX15B in response to the indicated
stimuli in S9 or IB3.1 cells. Data points are the means of 2−ΔΔCT±SEM (n=3).
* and + indicate p≤0.05 as compared to control and S9 cells, respectively.
Table 2
Fold change of phospholipase A2 and lipoxygenase gene expression in Af
sensitization/challenge, compared to PBS sensitized mice.
CFTR−/− C56BL/6 FVB
Pla2g2c 2.3±0.4 ⁎ 0.9±0.1 a –
Pla2g2d 3.2±0.9 ⁎ 1.4±0.3 a 0.7±0.2
Pla2g2e 1.2±0.2 1.7±0.2 ⁎ a 1.5±0.3
Pla2g5 3.6±0.5 ⁎ 1.9±0.3 ⁎ a 0.9±0.2
Pla2g10 1.1±0.3 1.0±0.2 a –
Pla2g12b 1.1±0.2 0.5±0.1 ⁎ a –
Pla2g4a 1.4±0.4 1.2±0.1 1.0±0.2
Pla2g4b 1.2±0.2 0.9±0.1 –
Pla2g4c 6.4±2.2 ⁎ 25.0±2.8 ⁎ 2.6±0.7
Ptgs1 1.4±0.2 0.9±0.3 –
Ptgs2 1.5±0.5 0.7±0.3 –
Ptges 1.8±0.6 2.2±0.7 –
Tbxas1 1.0±0.3 1.1±0.3 –
Ptgds 1.0±0.5 0.3±0.1 –
Ptgis 1.1±0.5 0.7±0.3 –
Aloxe3 1.2±0.3 0.7±0.1 ⁎ –
Alox5 0.9±0.1 1.2±0.2 –
Alox5ap 1.2±0.3 1.9±0.4 –
Alox12 0.6±0.1 0.5±0.1 ⁎ 0.4±0.1 ⁎
Alox12b 1.7±0.3 ⁎ 0.7±0.1 –
Alox15 4.2±0.6 ⁎ 30.1±6.1 ⁎ 3.1±0.8 ⁎
Alox8 3.6±0.8 ⁎ 4.7±0.6 ⁎ 0.8±0.3
Alox12e b 9.2±1.8 ⁎ 20.0±2.7 ⁎ 3.7±1.1 ⁎
Values represent means of 2−ΔΔCT±SEM.
⁎ p≤0.05 by Student's t-test.
a Originally published in Reference [20].
b Mouse ortholog of the human pseudogene ALOX12P.
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by its own product [39], very little is known about this enzyme's
regulation, thus making the induction in the Af-treated mice
and by IL-13 in the IB3.1 cells an intriguing observation. In
addition to its role in the synthesis of pro-inflammatory products,
15-lipoxygenases also participate through transcellular biosynthe-
sis in the production of anti-inflammatory bioactive lipid mediators
of resolution, the lipoxins [40–43]. Lipoxins, LXA4 and LXB4
being the main components, are lipid mediators generated from
AA that act to reduce inflammation and promote resolution.
Lipoxins are generated through the combined action of 5- and
15-lipoxygenases during cell–cell interactions. Recent data have
also demonstrated that lipoxin concentrations in CF patient's
airway fluid are significantly suppressed when compared to other
inflammatory lung conditions [40].
We therefore hypothesize that the coupled induction of
both Pla2g4c and the lipoxygenases in our mouse models of Af
sensitization/challenge provides for the generation of both
arachidonate and downstream lipoxygenase metabolites as potent
mediators in the pathology of ABPA, asthma and CF. To this end,
we have identified a number of genes in the eicosanoid pathway
that display altered gene expression that may be associated with
ABPA, allergic asthma or CF. The results have also helped to
highlight a PLA2G4C→lipoxygenase axis where the downstream
metabolites can act as potentially important mediators in the
inflammatory response in these diseases. Furthermore, the altered
expression of these genes provides potential identifiers and
therapeutic targets that are specifically linked to Aspergillus
sensitization and/or cystic fibrosis.Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.08.014.Conﬂict of interest
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